British pharmaceutical company GlaxoSmithKline is infusing $100 million its laboratory in Hamilton, Montana, U.S. to expand its long-term vaccine manufacturing capabilities.

With the investment, GSK intends to expand production capacity of key components of the adjuvant system used in several of its vaccines, including SHINGRIX, its shingles vaccine.

The deal will add a combination of temporary construction and contracting jobs, and new permanent positions including scientists, engineers and manufacturing and quality professionals.

GSK, which in 2018 booked about $40 billion in revenue, noted that the project is expected to run through 2022.